Senior Management

Shane J. Schaffer, PharmD is a Co-Founder of Cingulate Therapeutics and has served as the Chairman and CEO since its inception. Dr. Schaffer is a 25-year pharmaceutical industry veteran with experience in pharmaceutical drug development, commercialization and biotech commercial operations. During his career, he has held positions at Pfizer, Novartis and Sanofi (including predecessor companies).

Dr. Schaffer has broad functional and therapeutic expertise through the development and commercialization of several billion dollar brands including the ADHD Franchise of Ritalin® & Focalin®, Lipitor®, Lyrica®, Eligard®, Arixtra®, Hyalgan® and Avapro®/Avalide®. He has led the strategic brand planning, franchise resource allocation and managed care & reimbursement strategy for numerous products.

Dr. Schaffer received his Doctor of Pharmacy degree from the University of Kansas. He served as Chief Fellow and completed a Post-Doctoral Pharmaceutical Industry Fellowship at Rutgers University, College of Pharmacy in conjunction with Warner-Lambert/Parke-Davis, now Pfizer.

Raul R. Silva, MD is a Co-Founder of Cingulate Therapeutics and serves as CSO. He is a practicing child and adolescent psychiatrist who has served as Associate Professor and Vice Chairman of Child and Adolescent Psychiatry at New York University School of Medicine in New York City. Prior to that, he was the Executive Director of Rockland Children’s Psychiatric Center. He also served as the Deputy Director in the Division of Child and Adolescent Psychiatry at Bellevue Hospital Center, also in New York City.

Dr. Silva has authored/coauthored over 125 publications and presented at grand rounds and national meetings on over 120 occasions. He has been Principal Investigator and Co-Investigator for 21 research projects in his field.

Dr. Silva received his Doctor of Medicine degree from Ross University. He completed his fellowship in child and adolescent psychiatry at Columbia University’s St. Luke’s/Roosevelt Hospital Center where he became the director of service and residency training director. Dr. Silva completed a psychopharmacology research fellowship at New York University Medical Center. Dr. Silva is board certified in general, child and adolescent psychiatry.

Laurie A. Myers, Ph.D is a pharmaceutical executive and entrepreneur whose expertise spans all aspects of branded pharmaceutical life cycle management from drug development and commercialization to strategy and execution of global marketing plans.

Dr. Myers therapeutic expertise includes cardiovascular disease/thrombosis, osteoarthritis and oncology with additional aptitude in infectious disease, neurology/psychiatric disorders and asthma. She has played key role in drug development, marketing and commercialization for leading global pharmaceutical companies, including Novartis, DuPont, Pfizer and Sanofi (including predessor companies) which included leadership positions in both R&D and marketing. She has been named to the Top 100 Brand Champions by Pharma Voice.

Dr. Myers is a founding member of the Cingulate Therapeutics Board of Directors and has contributed to two investor organizations; Mid Atlantic Bio Angels and Mid Atlantic Diamond Ventures and was commercial advisor to another start-up, EpiGen Pharma.

Dr. Myers earned her PhD in Toxicology from Rutgers Medical School/Rutgers School of Pharmacy in New Jersey and an MBA in Pharmaceutical Marketing from St. Joseph’s University, Philadelphia, PA. She has served as Adjunct Professor at The College of New Jersey School of Business.

Matthew Brams, MD is Chief Medical Officer and a Co-Founder of Cingulate Therapeutics. Dr. Brams is Medical Director and Principal of Bayou City Research, Inc. There, he has been instrumental in gaining FDA approval of over 15 Central Nervous System drugs currently in the marketplace. Dr. Brams is also a Clinical Associate Professor at the Menninger Department of Psychiatry of Baylor College of Medicine and has published over 20 peer-reviewed journal articles.

He has been lead investigator in several pivotal trials involving drugs in ADHD, autism, bipolar disorder and schizophrenia therapeutic areas. He has extensive experience in drug development and execution of Phase I-IV trials and has been involved in over 125 clinical trials in both adult and pediatric populations in all areas of psychiatry. In addition, he has over 25 years of clinical experience managing patients in the field of Adult and Child Psychiatry with particular expertise in ADHD and Autistic Spectrum Disorders (ASD).

He earned his MD from the University of Texas Health Science Center in Houston and completed his residencies at Baylor College of Medicine. He is Board certified in Adult and Child Psychiatry and is a Senior Board Examiner for the American Board of Psychiatry and Neurology.

Jennifer Callahan was named Cingulate’s Chief Financial Officer in January 2024. She brings decades of finance and accounting experience to the C-Suite, serving as Vice President, Corporate Controller for Cingulate from 2017 until her promotion to CFO. Prior to her role at the Company, Jennifer served as the Director of Accounting for a local Kansas City area CPA firm. Over the tenure of her career, she has provided consulting services to companies in a variety of industries and stages, publicly and privately owned. Jennifer started her career with Deloitte where she served in various roles in the audit practice. Ms. Callahan holds a CPA designation and received a BSBA in Accounting and Finance from Creighton University in Omaha, Nebraska.